Premium
Protective effect of tetramethylpyrazine (TMP) on autosomal dominant polycystic kidney disease (ADPKD)
Author(s) -
ran jianhua,
He Guiqiong,
Sun Shanquan
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.727.7
Subject(s) - tetramethylpyrazine , autosomal dominant polycystic kidney disease , mtt assay , cytotoxicity , cell growth , mapk/erk pathway , western blot , pharmacology , cell , kidney , cyst , toxicity , in vitro , chemistry , cancer research , biology , medicine , microbiology and biotechnology , pathology , signal transduction , biochemistry , gene , alternative medicine
The study investigated the inhibited effect and possible mechanism of tetramethylpyrazine (TMP) on cyst development of autosomal dominant polycystic kidney disease (ADPKD) in vitro. The Madin‐Darby Canine Kidney (MDCK) cell cyst model was established to evaluate the inhibition activity of drug. Cell cytotoxicity and proliferation were detected by MTT assay and Cell Counting Kit (CCK) assay. Ras/MAPK signaling pathway‐related proteins was examined by Western blot. Results showed that the cyst inhibition of tetramethylpyrazine (IC50=0.158 ¦ÌM) with dose‐response relationship. Tetramethylpyrazine prevented forskolin‐promoted MDCK cell abnormal proliferation mainly by decreasing expression of B‐Raf and increasing expression of Raf‐1 to regulate level of p‐ERK at testing concentrations with no apparent toxicity. These results suggest that tetramethylpyrazine might be developed as novel candidate drugs for the treatment or mechanism study of ADPKD. Supported by the National Natural Science Foundation of China (30500171), and the Natural Science Foundation of Chongqing (CSTC2010BB5098).